Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Non-Current Deferred Tax Liability (2016 - 2021)

Historic Non-Current Deferred Tax Liability for Assembly Biosciences (ASMB) over the last 7 years, with Q3 2021 value amounting to $2.5 million.

  • Assembly Biosciences' Non-Current Deferred Tax Liability changed 0.0% to $2.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $2.5 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.5 million for FY2020, which is 0.0% changed from last year.
  • Assembly Biosciences' Non-Current Deferred Tax Liability amounted to $2.5 million in Q3 2021, which was down 0.0% from $2.5 million recorded in Q2 2021.
  • Assembly Biosciences' Non-Current Deferred Tax Liability's 5-year high stood at $3.3 million during Q4 2018, with a 5-year trough of $2.1 million in Q4 2017.
  • Its 5-year average for Non-Current Deferred Tax Liability is $2.7 million, with a median of $2.5 million in 2019.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first plummeted by 8079.08% in 2017, then surged by 5224.72% in 2018.
  • Over the past 5 years, Assembly Biosciences' Non-Current Deferred Tax Liability (Quarter) stood at $2.1 million in 2017, then skyrocketed by 52.25% to $3.3 million in 2018, then fell by 22.17% to $2.5 million in 2019, then changed by 0.0% to $2.5 million in 2020, then changed by 0.0% to $2.5 million in 2021.
  • Its Non-Current Deferred Tax Liability was $2.5 million in Q3 2021, compared to $2.5 million in Q2 2021 and $2.5 million in Q1 2021.